2018

PRODIGE 29 - UCGI 26 - NEOPAN: - A Randomised trial of chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma

Congress : ESMO

Authors : M. Ducreux, R. Desgrippes, M. Texier, F. Di Fiore, P. Vanelslander, O. Capitain, R. Guimbaud, J. Forestier, F. El Hajbi, P. Follana, A. Parzy, N. Baba Hamed, Y. Rinaldi, T. Brotelle, J.-P. Pignon, C. Jouffroy, L. Dahan, O. Bouche.

Experts group or program : Groupe gastro-intestinal (UCGI)

PC is an aggressive malignancy and the 4th cause of all cancer deaths worldwide. More than 30% of patients with PC are unresectable because of the local extension with a median overall survival (OS) of less than one year. The standard of care remains gemcitabine (gem) alone. 5FU, irinotecan, oxaliplatin (Folfirinox) is superior to gemcitabine in the treatment of metastatic PC, in terms of OS and progression-free survival (PFS).

En savoir plus